Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 11/20 | 0.55 |
| ▸ | ALOX5AP | P20292 | 7/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21000574 | 0.89 | FEN1 (0.53) | FEN1ALOX5APALDH1A1BACE1PTPRC | |
| SCHEMBL396633 | 0.88 | FEN1 (0.55) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29647556 | 0.88 | FEN1 (0.55) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL21715763 | 0.83 | ALDH1A1 (0.46) | FEN1ALOX5APALDH1A1MAP4K4 | |
| SCHEMBL3787019 | 0.83 | ALDH1A1 (0.52) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL3904951 | 0.82 | FEN1 (0.51) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5993403 | 0.82 | ALOX5AP (0.56) | FEN1ALOX5APALDH1A1BACE1 | |
| SCHEMBL977502 | 0.81 | ALDH1A1 (0.54) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5556308 | 0.80 | MEN1 (0.59) | FEN1ALOX5APALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL18601376 | 0.80 | KIF11 (0.59) | FEN1ALOX5APALDH1A1HSD17B10BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | FEN1 2139/4885ALOX5AP 2385/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.